"Red chip of state owned enterprises" Shanghai Pharmaceutical (02607) acquires the antitumor drug of yew extract
-
Last Update: 2015-03-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Shanghai Pharmaceutical (02607) (Shanghai: 601607) announced that in order to integrate the anti-tumor drug industry chain of Shanghai Pharmaceutical and develop gap planting base of traditional Chinese medicine, Shanghai Huayu pharmaceutical, a wholly-owned subsidiary of Shanghai pharmaceutical, and Shanghai Jin and biotechnology, a holding subsidiary of Shanghai Jin and biotechnology, invested RMB 160.1 million and RMB 110 million respectively in cash, through the transfer of Yunnan dalikangya biotechnology The way of equity and capital increase of Dali Zhonggu Taxus biology ultimately obtained 40% equity and 27.5% equity of Zhonggu biology to realize the holding of Zhonggu biology Zhonggu biological's business scope includes: Taxus, planting, sales, and preparation of processing projects Its main business is planting and selling rare Taxus chinensis, which can extract the key intermediate of antitumor drugs, 10dabiii Zhonggu biological's core assets are nearly 5.52 million Taxus seedlings and trees in Dali Prefecture, Yunnan Province, and related forest land use rights (EC)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
